These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Targeted therapies in the treatment of non small cell lung cancer: reality and hopes. Gridelli C Curr Opin Oncol; 2004 Mar; 16(2):126-9. PubMed ID: 15075903 [No Abstract] [Full Text] [Related]
11. Targeted therapy in advanced non-small cell lung cancer (NSCLC): where do we stand? Azim HA; Ganti AK Cancer Treat Rev; 2006 Dec; 32(8):630-6. PubMed ID: 17034953 [TBL] [Abstract][Full Text] [Related]
12. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance. Jotte RM; Spigel DR Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719 [TBL] [Abstract][Full Text] [Related]
13. The role of targeted therapy in non-small cell lung cancer. Maione P; Rossi A; Airoma G; Ferrara C; Castaldo V; Gridelli C Crit Rev Oncol Hematol; 2004 Jul; 51(1):29-44. PubMed ID: 15207252 [TBL] [Abstract][Full Text] [Related]
14. [New advance of the molecular targeting agents in advanced non-small cell lung cancer]. Zhang L; Cheng ZW; Gao JM Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Jun; 26(3):323-9. PubMed ID: 15266840 [TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. Lee JK; Hahn S; Kim DW; Suh KJ; Keam B; Kim TM; Lee SH; Heo DS JAMA; 2014 Apr; 311(14):1430-7. PubMed ID: 24715074 [TBL] [Abstract][Full Text] [Related]
16. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323 [TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor as a target to improve treatment of lung cancer. Andratschke NH; Dittmann KH; Mason KA; Fan Z; Liao Z; Komaki R; Ang KK; Milas L Clin Lung Cancer; 2004 May; 5(6):340-52. PubMed ID: 15217533 [TBL] [Abstract][Full Text] [Related]
18. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective. Raben D; Helfrich B; Bunn PA Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632 [TBL] [Abstract][Full Text] [Related]
19. Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor. Kelly K; Huang C J Thorac Oncol; 2008 Jun; 3(6):664-73. PubMed ID: 18520811 [TBL] [Abstract][Full Text] [Related]
20. A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer. Govindan R Clin Lung Cancer; 2010 Jan; 11(1):8-12. PubMed ID: 20085861 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]